Literature DB >> 14664772

Visual Hallucinations.

Victoria S. Pelak1, Grant T. Liu.   

Abstract

Neurologists and ophthalmologists should be familiar with the causes and treatment of visual hallucinations so that they are able to reassure patients and minimize the anguish associated with untreated visual hallucinations. Hallucinations are under-reported by patients because of the perceived psychiatric implication or because of poor insight into the unreal nature of the hallucinations. In the appropriate setting, physicians should specifically inquire about hallucinations as well as initiate medical treatment. Visual hallucinations have many etiologies and are associated with a variety of disorders. Identification of the associated disorder or cause is necessary to determine the appropriate treatment. Causes and associated disorders include ocular phenomena, migraine, seizures, visual loss (ie, release hallucinations), neurodegenerative disorders, midbrain injury, alcohol and drug effects, narcolepsy, post-traumatic stress disorder, and psychosis. Therapeutic treatment should be directed at the associated disorder or etiology. For instance, antiepileptic drugs may be appropriate for patients with irritative phenomena such as seizures and visual aura of migraine. Depending on the cause, other agents are available and include neuroleptics, cholinesterase inhibitors, and acetazolamide. Well-designed, randomized, controlled clinical trials regarding treatment of visual hallucinations associated with various disorders are lacking. Although complete resolution of visual hallucinations can be difficult, even minimal improvement may be symptomatically beneficial.

Entities:  

Year:  2004        PMID: 14664772     DOI: 10.1007/s11940-004-0041-4

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  26 in total

1.  The neural basis of Charles Bonnet hallucinations: a hypothesis.

Authors:  W Burke
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-11       Impact factor: 10.154

2.  Successful treatment of persistent migraine aura with divalproex sodium.

Authors:  J F Rothrock
Journal:  Neurology       Date:  1997-01       Impact factor: 9.910

Review 3.  Visual perceptual abnormalities: hallucinations and illusions.

Authors:  J W Norton; J J Corbett
Journal:  Semin Neurol       Date:  2000       Impact factor: 3.420

Review 4.  Cholinesterase inhibitors: A new class of psychotropic compounds.

Authors:  J L Cummings
Journal:  Am J Psychiatry       Date:  2000-01       Impact factor: 18.112

5.  Visual symptoms in the migraine syndrome.

Authors:  V C Hachinski; J Porchawka; J C Steele
Journal:  Neurology       Date:  1973-06       Impact factor: 9.910

6.  Persistent positive visual phenomena in migraine.

Authors:  G T Liu; N J Schatz; S L Galetta; N J Volpe; F Skobieranda; G S Kosmorsky
Journal:  Neurology       Date:  1995-04       Impact factor: 9.910

7.  Donepezil in the treatment of hallucinations and delusions in Parkinson's disease.

Authors:  G Fabbrini; P Barbanti; C Aurilia; C Pauletti; G L Lenzi; G Meco
Journal:  Neurol Sci       Date:  2002-04       Impact factor: 3.307

Review 8.  Therapeutics in pediatric epilepsy, Part 1: The new antiepileptic drugs and the ketogenic diet.

Authors:  Randa G Jarrar; Jeffrey R Buchhalter
Journal:  Mayo Clin Proc       Date:  2003-03       Impact factor: 7.616

9.  Digoxin toxicity. Recognizing the varied visual presentations.

Authors:  J R Piltz; C Wertenbaker; S E Lance; T Slamovits; H F Leeper
Journal:  J Clin Neuroophthalmol       Date:  1993-12

Review 10.  Neuropsychiatric symptoms in the dementias.

Authors:  Frédéric Assal; Jeffrey L Cummings
Journal:  Curr Opin Neurol       Date:  2002-08       Impact factor: 5.710

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.